$Neuralstem Inc(CUR)$ Neuralstem, Inc. HOME ABOUT PLATFORM PIPELINE NEWS & MEDIA INVESTORS CONTACT NEWS & MEDIA Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting DOWNLOAD AS PDF DECEMBER 05, 2017 40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory Two additional self-rated secondary endpoints (CPFQ and QIDS) showed statistically significant improvements in depressive symptoms with procognitive benefits, reinforcing the benefit with SDQ endpoint reported previously NSI-189 appeared to be safe and well tolerated with no serious adverse events The Company will be hosting a conference cal